Blue Belt Robotic Surgery Buy Is A 'Must-Have,' Says Smith & Nephew
This article was originally published in The Gray Sheet
S&N will pay $275 million to buy Blue Belt, which is still in the red and is expected to generate only $19 million in revenue for 2015 through sales of its Navio surgical system. The firm's sales team has been vocal in support of acquiring the technology, executives said.
You may also be interested in...
Market Intel: Rivals Catching Up To Intuitive Surgical In Fast-Growing, Fast-Innovating Robotic-Assisted Devices Market
The global market for robotically assisted systems (RAS) is expected to reach $5.3bn by 2021, a CAGR of 11.7%. Meddevicetracker expects this hot market, long-dominated by Intuitive Surgical's da Vinci systems, to see rising competition from innovative companies developing robotic systems that are smaller, portable and less costly and offer surgeons innovative features that allow them to perform even more precise and user-friendly, complex surgeries. In this feature, we'll take a closer look at the overall market, highlighting the competitive landscape as well as limiters and growth opportunities. We'll also take a deep dive into RAS systems and their applications. Surgeons of various specialties provide key insights about the pros and cons of different systems.
French ortho medical imaging specialist EOS imaging has made two new senior leadership appointments. Mike Lobinsky joins in a newly created role as US President while Pierre Schwich has been hired as the company's new CFO.
Yuhan’s oncology drug lazertinib is set to expand its indications in Korea to the first-line treatment of EGFR mutation-positive advanced NSCLC, based on new top-line Phase III data showing clinical benefits for all patient sub-groups.